Loading...
Regeneron Pharmaceuticals, Inc.
0R2M.L•LSE
Healthcare
Medical - Pharmaceuticals
£526.06
£5.21(1.000%)
Regeneron Pharmaceuticals, Inc. (0R2M.L) Financial Performance & Statements
Review Regeneron Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
8.27%
↑ 8.27%
Operating Income Growth
-1.39%
↓ 1.39%
Net Income Growth
11.61%
↑ 11.61%
Operating Cash Flow Growth
-3.78%
↓ 3.78%
Operating Margin
27.37%
↑ 27.37%
Gross Margin
84.94%
↑ 84.94%
Net Profit Margin
31.94%
↑ 31.94%
ROE
14.77%
↑ 14.77%
ROIC
11.35%
↑ 11.35%
Regeneron Pharmaceuticals, Inc. (0R2M.L) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Regeneron Pharmaceuticals, Inc. stock.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $3.03B | $3.79B | $3.72B | $3.55B |
| Cost of Revenue | $211.10M | $565.40M | $491.10M | $600.90M |
| Gross Profit | $2.82B | $3.22B | $3.23B | $2.95B |
| Gross Profit Ratio | $0.93 | $0.85 | $0.87 | $0.83 |
| R&D Expenses | $1.33B | $1.41B | $1.27B | $1.08B |
| SG&A Expenses | $633.00M | $792.20M | $714.40M | $758.80M |
| Operating Expenses | $1.96B | $2.23B | $2.05B | $1.85B |
| Total Costs & Expenses | $2.17B | $2.80B | $2.54B | $2.45B |
| Interest Income | $0.00 | $183.10M | $187.40M | $179.40M |
| Interest Expense | -$8.70M | $10.50M | $13.80M | $14.80M |
| Depreciation & Amortization | -$304.60M | $126.40M | $121.70M | $120.70M |
| EBITDA | $591.70M | $1.09B | $1.63B | $1.21B |
| EBITDA Ratio | $0.20 | $0.29 | $0.44 | $0.34 |
| Operating Income | $591.70M | $990.20M | $1.18B | $1.09B |
| Operating Income Ratio | $0.20 | $0.26 | $0.32 | $0.31 |
| Other Income/Expenses (Net) | $313.30M | -$32.10M | $313.50M | $558.50M |
| Income Before Tax | $905.00M | $958.10M | $1.49B | $1.63B |
| Income Before Tax Ratio | $0.30 | $0.25 | $0.40 | $0.46 |
| Income Tax Expense | $96.30M | $40.40M | $152.40M | $195.80M |
| Net Income | $808.70M | $917.70M | $1.34B | $1.43B |
| Net Income Ratio | $0.27 | $0.24 | $0.36 | $0.40 |
| EPS | $7.58 | $8.53 | $12.40 | $13.25 |
| Diluted EPS | $7.27 | $8.06 | $11.54 | $12.41 |
| Weighted Avg Shares Outstanding | $106.70M | $107.90M | $108.10M | $108.10M |
| Weighted Avg Shares Outstanding (Diluted) | $111.20M | $115.10M | $116.20M | $115.40M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan